What the FDA labels say about taking them together
Flumazenil and triazolam
Triazolam's FDA label of July 10, 2026 names flumazenil in its warnings and precautions section; flumazenil's label does not name triazolam itself but warns about its class (Benzodiazepines). The triazolam label: “Abrupt discontinuation or rapid dosage reduction of triazolam after continued use, or administration of flumazenil may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures).”
Check it at the source: the flumazenil FDA label on DailyMed (effective June 21, 2024, Hikma Pharmaceuticals USA Inc.); the triazolam FDA label on DailyMed (effective July 10, 2026, Mylan Pharmaceuticals Inc.).
What does the flumazenil label say about triazolam?
Flumazenil's label does not name triazolam itself; it warns about its class (Benzodiazepines):
Flumazenil label, contraindicationsCONTRAINDICATIONS Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS ).
Flumazenil label, boxed warningTHESE ARE MOST FREQUENT IN PATIENTS WHO HAVE BEEN ON BENZODIAZEPINES FOR LONG-TERM SEDATION OR IN OVERDOSE CASES WHERE PATIENTS ARE SHOWING SIGNS OF SERIOUS CYCLIC ANTIDEPRESSANT OVERDOSE.
Source: FDA drug label (Flumazenil), Hikma Pharmaceuticals USA Inc., effective June 21, 2024 (SPL set 436f5616-9626-4b6a-9deb-2986444179d0), via openFDA; the full label on DailyMed
What does the triazolam label say about flumazenil?
Triazolam label, warnings and precautionsAbrupt discontinuation or rapid dosage reduction of triazolam after continued use, or administration of flumazenil (a benzodiazepine antagonist) may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures) [see Drug Abuse and Dependence (9.3) ].
Source: FDA drug label (Triazolam), NDA017892 (Pfizer), as published by Mylan Pharmaceuticals Inc., effective July 10, 2026 (SPL set 5add318e-11b9-42f8-b052-0d8cebb32fcf), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Flumazenil | Triazolam | |
|---|---|---|
| Labeled for | n/a | Insomnia |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $1.18 per mL 0.5 mg/5 mL vial | $0.308 per tablet 0.25 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once